PRNewsWire
08 Oct 2026, 20:34 UTC · 1h ago
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
Impact · against what's priced in
The futility finding in the UNITY study is a negative catalyst for argenx, as it removes a potential growth driver for subcutaneous Vyvgart that could have exceeded the current decelerating revenue baseline. Positive Phase 2 results for FB102 provide a slight offset, as the market was not previously pricing in the pipeline potential of that drug.
- ARGX−0.50
Challenges what's priced in
- The price assumes





